🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHas anyone dealt with glp-1 and peripheral arterial disease? Page 4

Has anyone dealt with glp-1 and peripheral arterial disease?

traveltech_sara Fri, Jan 31, 2025 at 6:48 PM 24 replies 2,011 viewsPage 4 of 5
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Feb 5, 2025 at 2:29 AM#16

Adding the clinical framing, because it changes how the question reads.

Senior perspective on cardiovascular risk: I'm 69 years old and started this journey skeptically. My geriatrician recommended it after years of failed interventions.

9 months later: down 37 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

45 18VanRx_Mike, steve_okc, dave_SLC and 42 others
Reply Quote Save Share Report
DeniseRN_TPA
Member
345
1,567
Aug 2024
Tampa, FL
Feb 5, 2025 at 5:29 PM#17
bri_stats said:
SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk.

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 52" → 34" ✅ Resolved
  2. Triglycerides: 248 → 98 ✅ Resolved
  3. HDL: 36 → 60 ✅ Resolved
  4. Blood pressure: 148/90 → 121/75 ✅ Resolved
  5. Fasting glucose: 128 → 88 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

46 19hyun_seoul, jim_asheville, matt_MKE and 43 others
Reply Quote Save Share Report
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Feb 6, 2025 at 8:29 AM#18
bri_stats said:
SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -1.8 lbs/week average
Fasting glucose (finger stick): stable at 85 mg/dL
Blood pressure (home): 118/75 average
Resting heart rate: 65 bpm (down from 81)
Waist circumference: down 15 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

47 20LondonLisa, mike_nyc, VendorMark and 44 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Feb 6, 2025 at 11:30 PM#19

One thing that is still open after bri_stats’s answer:

How would you tell the difference between that and the alternative explanation?

48 21LeilaHI, marcus_mpls, DeniseRN_TPA and 45 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Feb 7, 2025 at 2:31 PM#20

Moderator note: the sourcing question belongs in the vendor section and has been split out. Report rather than reply if it drifts again.

20 18PurityPaulOR, MaxMetOK, MounjBrad and 17 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register